Zoetis Inc. (ZTS)
| Market Cap | 72.31B |
| Revenue (ttm) | 9.29B |
| Net Income (ttm) | 2.52B |
| Shares Out | 445.21M |
| EPS (ttm) | 5.57 |
| PE Ratio | 29.18 |
| Forward PE | 25.72 |
| Dividend | $2.00 (1.23%) |
| Ex-Dividend Date | Apr 21, 2025 |
| Volume | 1,435,779 |
| Open | 161.03 |
| Previous Close | 159.27 |
| Day's Range | 160.68 - 164.59 |
| 52-Week Range | 139.70 - 200.33 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 213.00 (+31.14%) |
| Earnings Date | May 6, 2025 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $213.0, which is an increase of 31.14% from the latest price.
News
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Zoetis' Q1: Market Overreaction Or Justified Drop?
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of...
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company ...
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny J...
Zoetis raises forecast for 2025 revenue, profit on weaker US dollar
Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U....
Zoetis Announces First Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company...
Zoetis: Unleashing Margin Expansion; Initiate Strong Buy
We initiate coverage on Zoetis with a Strong Buy rating and a $219.26 price target, driven by explosive growth in companion animal products and structural margin expansion. Zoetis's leadership in comp...
Elanco vs Zoetis stock: Sarat Sethi picks a side
Zoetis Inc (NYSE: ZTS) is a relatively better pick than Elanco Animal Health Inc (NYSE: ELAN) for those interested in gaining exposure to the pets category, says Sarat Sethi. He's a managing partner a...
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% ...
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck...
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humaniza...
Zoetis: Focusing On The High Margin Segments
The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela labe...
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Zoetis Inc. (NYSE:ZTS) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Bar...
My Top 15 High-Growth Dividend Stocks For March 2025
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear ...
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript)
Zoetis Inc. (NYSE:ZTS) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America O...
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of ...
Zoetis CEO on bird flu vaccine
Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say
US grants conditional clearance to Zoetis' bird flu vaccine for poultry
Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.
Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #HPAI--Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional lice...
Zoetis CEO says Avian Flu vaccine for poultry gets USDA approval
Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more.
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing powe...
Zoetis Inc. (ZTS) Q4 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Steve Frank - IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Michael...
Zoetis Drops As 2025 Guidance Falls Short Of Estimates
On Thursday, Zoetis Inc ZTS reported a fourth-quarter 2024 adjusted EPS of $1.40, up from $1.24 a year ago, beating the consensus of $1.34.